// App-Quantinova.ai

: A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Researchers

Presenter

  • Kristen M. Pettit

Principal Investigators

  • Abdulraheem Yacoub

  • Terrence Bradley

  • Aaron T. Gerds

  • Maciej Tatarczuch

  • Jake Shortt

  • Natasha Joan Curtin

  • James M. Rossetti

  • Kate Burbury

  • Adam J Mead

  • Joachim R Göthert

  • Steffen Koschmieder

  • Matt Reyer

  • Benjamin Siranosian

  • Georges Natsoulis

  • William S Stevenson

  • Joanne Ewing

  • Joseph M. Chacko

  • Elisa Rumi

  • Anna B. Halpern

  • Francesca Palandri

  • Nicola Vianelli

  • Francesco Passamonti

  • Ruben Mesa

  • Monia Marchetti

  • Claire Harrison

  • Alessandro M. Vannucchi

  • Justin Watts

  • David M Ross

  • Moshe Talpaz

  • Hugh Young Rienhoff

Medical Centers

  • Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL

  • CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Firenze, Italy

  • Peter MacCallum Cancer Centre, MELBOURNE, Australia

  • Department of Medicine, The University of Hong Kong, Hong KOng, Hong Kong

  • Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI

  • Department of Haematology, Royal North Shore Hospital, Sydney, Australia

  • Hematology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy

  • Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, University Hospital of Aachen, Aachen, Germany

  • Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

  • Department of Haematology, Flinders Medical Centre and University, Adelaide, Australia

  • Monash Health, Monash University, Melbourne, Australia

  • UPMC Hillman Cancer Center, Pittsburgh, PA

  • Mays Cancer Center at UT Health San Antonio, San Antonio, TX

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Guy's and St Thomas’ NHS Foundation Trust, London, United Kingdom

  • University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL

  • Medical Research Council Weatherall Institute of Molecular Medicine and NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  • Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L. e A. Seragnoli, Hematology, Bologna, Italy

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Department of Medicine, University of Washington, Seattle, WA

  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

  • School of Clinical Sciences at Monash Health, Peter MacCallum Cancer Centre, Clayton, Australia

  • The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom

  • Hematology Unit & TMO Center, AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

  • Monash Health, Melbourne, Australia

  • The University of Kansas Cancer Center, Leawood, KS

Locations

  • United States

  • United Kingdom

  • Italy

  • Germany

  • Australia

  • Hong Kong

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

  • Myeloid neoplasms

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Calreticulin

  • Enhancer of zeste homolog 2

  • Lysine-specific histone demethylase 1A

  • Transcription factor Maf

  • Isocitrate dehydrogenase 1

  • Janus kinase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Red Blood Cells

  • Sustained virological response

Drug/Treatment

  • Ruxolitinib phosphate

  • EZH2

Outcome

  • N/A

Study Design

  • Safety

  • Open Label

  • Tolerability

  • Controlled

  • Global

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved